Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087

Robert Chen; Phillippe Armand; Michelle A Fanale; Vincent Ribrag; Pier Luigi Zinzani; Alejandro D Ricart; Seth Thompson; Arun Balakumaran; Daniel Molin; Margaret A Shipp; Craig H Moskowitz

首页> 外文期刊>Journal for ImmunoTherapy of Cancer >Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087

【24h】

Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087

机译：派姆单抗（MK-3475）用于复发/难治性经典霍奇金淋巴瘤（r / r cHL）的II期研究：主题演讲087

获取原文

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Journal for ImmunoTherapy of Cancer》 |2015年第s2期|共页
作者
Robert Chen; Phillippe Armand; Michelle A Fanale; Vincent Ribrag; Pier Luigi Zinzani; Alejandro D Ricart; Seth Thompson; Arun Balakumaran; Daniel Molin; Margaret A Shipp; Craig H Moskowitz;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study [J] . Moskowitz Craig H., Zinzani Pier Luigi, Fanale Michelle A., Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：Pembrolizumab在复发/难治性经典霍奇金淋巴瘤中的应用：2期Keynote-087研究的主要终点分析
2. Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis [J] . Zinzani Pier Luigi, Chen Robert, Armand Philippe, Leukemia and lymphoma . 2020,第3a4期

机译：Pembrolizumab单药治疗初级耐火经典霍奇金淋巴瘤淋巴瘤，后者复制后复制后爆发性干细胞移植和/或Brentuximab Vedotin治疗：Keynote-087亚组分析
3. Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study [J] . Armand Philippe, Engert Andreas, Younes Anas, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：在自体造血细胞移植后的复发或难治性经典霍奇金淋巴瘤（CHL）的Nivolumab（Auto-Hct）：延长相2单臂的延长随访205研究
4. Autotransplant Approach with Rituximab in High Grade Primary Refractory or Progressive Non Hodgkin's Lymphomas (NHL). 2nd Report [C] . D. Vallisa, A. Lazzaro, R. Berte, European Haematology Association . 2002

机译：用Rituximab在高级初级耐火或渐进非霍奇金淋巴瘤（NHL）中的rituximab的自同毒性方法。第二次报告
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087 [O] . Robert Chen, Phillippe Armand, Michelle A Fanale, 2015

机译：派姆单抗（MK-3475）用于复发/难治性经典霍奇金淋巴瘤（r / r cHL）的II期研究：主题演讲087
7. Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087 [O] . 2015

机译：派姆单抗（MK-3475）用于复发/难治性经典霍奇金淋巴瘤（r / r cHL）的II期研究：主题演讲087

相关主题

Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087

著录项

引文网络

相似文献

相关主题

期刊订阅